Summary of Study ST003015
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001876. The data can be accessed directly via it's Project DOI: 10.21228/M87426 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST003015 |
Study Title | NMR- and MS-based omics reveal characteristic metabolome atlas and optimize biofluid earlydiagnostic biomarkers for esophageal squamous cell carcinoma (part-Ⅰ) |
Study Summary | Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. We conducted NMR- and MS-based metabolomics on 1,153 matched ESCC tissues, normal mucosae, pre- and one-week post-operative sera and urines from 560 participants across three hospitals, with machine learning, logistic regression and WGCNA. Aberrations in 'alanine, aspartate and glutamate metabolism' proved to be prevalent throughout the ESCC evolution, and were reflected in 16 serum and 10 urine metabolic signatures that were consistently identified by NMR and MS in both discovery and validation sets. NMR-based simplified panels of any five serum or urine metabolites outperformed clinical serological tumor markers (AUC = 0.984 and 0.930, respectively), and were effective in distinguishing early-stage ESCC in test set (serum accuracy = 0.994, urine accuracy = 0.879). Collectively, NMR-based biofluid screening can reveal characteristic metabolic events of ESCC and be feasible for early detection (ChiCTR2300073613). |
Institute | Shantou University Medical College |
Department | Radiology Department, Second Affiliated Hospital |
Last Name | Lin |
First Name | Yan |
Address | No. 69, Dongxia North Road, Shantou, Guangdong, China |
994809889@qq.com | |
Phone | +86 18823992148 |
Submit Date | 2023-12-16 |
Raw Data Available | Yes |
Raw Data File Type(s) | fid |
Analysis Type Detail | NMR |
Release Date | 2024-02-08 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001876 |
Project DOI: | doi: 10.21228/M87426 |
Project Title: | NMR- and MS-based omics reveal characteristic metabolome atlas and optimize biofluid earlydiagnostic biomarkers for esophageal squamous cell carcinoma |
Project Summary: | Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. We conducted NMR- and MS-based metabolomics on 1,153 matched ESCC tissues, normal mucosae, pre- and one-week post-operative sera and urines from 560 participants across three hospitals, with machine learning, logistic regression and WGCNA. Aberrations in 'alanine, aspartate and glutamate metabolism' proved to be prevalent throughout the ESCC evolution, and were reflected in 16 serum and 10 urine metabolic signatures that were consistently identified by NMR and MS in both discovery and validation sets. NMR-based simplified panels of any five serum or urine metabolites outperformed clinical serological tumor markers (AUC = 0.984 and 0.930, respectively), and were effective in distinguishing early-stage ESCC in test set (serum accuracy = 0.994, urine accuracy = 0.879). Collectively, NMR-based biofluid screening can reveal characteristic metabolic events of ESCC and be feasible for early detection (ChiCTR2300073613). |
Institute: | Radiology Department, Second Affiliated Hospital, Shantou University Medical College |
Last Name: | Lin |
First Name: | Yan |
Address: | No. 69, Dongxia North Road, Shantou, Guangdong, China |
Email: | 994809889@qq.com |
Phone: | +86 18823992148 |
Subject:
Subject ID: | SU003129 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Fator |
---|---|---|
SA327463 | 20220725.73.fid#73 | Normal tissue |
SA327464 | 20220725.74.fid#74 | Normal tissue |
SA327465 | 20220725.72.fid#72 | Normal tissue |
SA327466 | 20220725.71.fid#71 | Normal tissue |
SA327467 | 20220725.70.fid#70 | Normal tissue |
SA327468 | 20220725.75.fid#75 | Normal tissue |
SA327469 | 20220725.77.fid#77 | Normal tissue |
SA327470 | 20220725.80.fid#80 | Normal tissue |
SA327471 | 20220725.81.fid#81 | Normal tissue |
SA327472 | 20220725.79.fid#79 | Normal tissue |
SA327473 | 20220725.78.fid#78 | Normal tissue |
SA327474 | 20220725.69.fid#69 | Normal tissue |
SA327475 | 20220725.76.fid#76 | Normal tissue |
SA327476 | 20220725.68.fid#68 | Normal tissue |
SA327477 | 20220725.60.fid#60 | Normal tissue |
SA327478 | 20220725.61.fid#61 | Normal tissue |
SA327479 | 20220725.59.fid#59 | Normal tissue |
SA327480 | 20220725.58.fid#58 | Normal tissue |
SA327481 | 20220725.57.fid#57 | Normal tissue |
SA327482 | 20220725.62.fid#62 | Normal tissue |
SA327483 | 20220725.63.fid#63 | Normal tissue |
SA327484 | 20220725.67.fid#67 | Normal tissue |
SA327485 | 20220725.66.fid#66 | Normal tissue |
SA327486 | 20220725.65.fid#65 | Normal tissue |
SA327487 | 20220725.64.fid#64 | Normal tissue |
SA327488 | 20220725.82.fid#82 | Normal tissue |
SA327489 | 20220725.84.fid#84 | Normal tissue |
SA327490 | 20220725.100.fid#100 | Normal tissue |
SA327491 | 20220725.101.fid#101 | Normal tissue |
SA327492 | 20220725.99.fid#99 | Normal tissue |
SA327493 | 20220725.98.fid#98 | Normal tissue |
SA327494 | 20220725.97.fid#97 | Normal tissue |
SA327495 | 20220725.102.fid#102 | Normal tissue |
SA327496 | 20220725.103.fid#103 | Normal tissue |
SA327497 | 20220725.107.fid#107 | Normal tissue |
SA327498 | 20220725.108.fid#108 | Normal tissue |
SA327499 | 20220725.106.fid#106 | Normal tissue |
SA327500 | 20220725.105.fid#105 | Normal tissue |
SA327501 | 20220725.104.fid#104 | Normal tissue |
SA327502 | 20220725.96.fid#96 | Normal tissue |
SA327503 | 20220725.95.fid#95 | Normal tissue |
SA327504 | 20220725.87.fid#87 | Normal tissue |
SA327505 | 20220725.88.fid#88 | Normal tissue |
SA327506 | 20220725.86.fid#86 | Normal tissue |
SA327507 | 20220725.85.fid#85 | Normal tissue |
SA327508 | 20220725.56.fid#56 | Normal tissue |
SA327509 | 20220725.89.fid#89 | Normal tissue |
SA327510 | 20220725.90.fid#90 | Normal tissue |
SA327511 | 20220725.94.fid#94 | Normal tissue |
SA327512 | 20220725.93.fid#93 | Normal tissue |
SA327513 | 20220725.92.fid#92 | Normal tissue |
SA327514 | 20220725.91.fid#91 | Normal tissue |
SA327515 | 20220725.83.fid#83 | Normal tissue |
SA327516 | 20220725.55.fid#55 | Normal tissue |
SA327517 | 20220725.19.fid#19 | Tumor tissue |
SA327518 | 20220725.20.fid#20 | Tumor tissue |
SA327519 | 20220725.18.fid#18 | Tumor tissue |
SA327520 | 20220725.17.fid#17 | Tumor tissue |
SA327521 | 20220725.16.fid#16 | Tumor tissue |
SA327522 | 20220725.21.fid#21 | Tumor tissue |
SA327523 | 20220725.22.fid#22 | Tumor tissue |
SA327524 | 20220725.26.fid#26 | Tumor tissue |
SA327525 | 20220725.27.fid#27 | Tumor tissue |
SA327526 | 20220725.25.fid#25 | Tumor tissue |
SA327527 | 20220725.24.fid#24 | Tumor tissue |
SA327528 | 20220725.23.fid#23 | Tumor tissue |
SA327529 | 20220725.15.fid#15 | Tumor tissue |
SA327530 | 20220725.14.fid#14 | Tumor tissue |
SA327531 | 20220725.5.fid#5 | Tumor tissue |
SA327532 | 20220725.6.fid#6 | Tumor tissue |
SA327533 | 20220725.4.fid#4 | Tumor tissue |
SA327534 | 20220725.3.fid#3 | Tumor tissue |
SA327535 | 20220725.2.fid#2 | Tumor tissue |
SA327536 | 20220725.7.fid#7 | Tumor tissue |
SA327537 | 20220725.8.fid#8 | Tumor tissue |
SA327538 | 20220725.12.fid#12 | Tumor tissue |
SA327539 | 20220725.13.fid#13 | Tumor tissue |
SA327540 | 20220725.11.fid#11 | Tumor tissue |
SA327541 | 20220725.10.fid#10 | Tumor tissue |
SA327542 | 20220725.9.fid#9 | Tumor tissue |
SA327543 | 20220725.28.fid#28 | Tumor tissue |
SA327544 | 20220725.29.fid#29 | Tumor tissue |
SA327545 | 20220725.46.fid#46 | Tumor tissue |
SA327546 | 20220725.47.fid#47 | Tumor tissue |
SA327547 | 20220725.45.fid#45 | Tumor tissue |
SA327548 | 20220725.44.fid#44 | Tumor tissue |
SA327549 | 20220725.43.fid#43 | Tumor tissue |
SA327550 | 20220725.48.fid#48 | Tumor tissue |
SA327551 | 20220725.49.fid#49 | Tumor tissue |
SA327552 | 20220725.53.fid#53 | Tumor tissue |
SA327553 | 20220725.54.fid#54 | Tumor tissue |
SA327554 | 20220725.52.fid#52 | Tumor tissue |
SA327555 | 20220725.51.fid#51 | Tumor tissue |
SA327556 | 20220725.50.fid#50 | Tumor tissue |
SA327557 | 20220725.42.fid#42 | Tumor tissue |
SA327558 | 20220725.41.fid#41 | Tumor tissue |
SA327559 | 20220725.33.fid#33 | Tumor tissue |
SA327560 | 20220725.34.fid#34 | Tumor tissue |
SA327561 | 20220725.32.fid#32 | Tumor tissue |
SA327562 | 20220725.31.fid#31 | Tumor tissue |
Collection:
Collection ID: | CO003122 |
Collection Summary: | Tissue samples, including tumor and normal areas 5 cm away, were obtained under the guidance of experienced pathologists without compromising the patients' pathology examinations. The collected tissue was rinsed with PBS to avoid contamination, excess moisture was removed, and it was rapidly frozen in liquid nitrogen to arrest enzymatic or chemical reactions. Samples were stored at −80°C until metabolite extraction. |
Collection Protocol Filename: | Tissue_collection_uploaded.pdf |
Sample Type: | Tissue |
Storage Conditions: | -80℃ |
Treatment:
Treatment ID: | TR003138 |
Treatment Summary: | None |
Sample Preparation:
Sampleprep ID: | SP003135 |
Sampleprep Summary: | Tissue homogenate preparation: Tissue samples weighing 300 mg were ground using a 60 Hz grinder at 4 °C for 1 min in a mixture of 4 mL/g of CH3OH and 2 mL/g of ultrapure water. The resulting homogenate was then subjected to vortexing for 1 min after adding 4 mL/g of CHCl3 and 4 mL/g of ultrapure water. The mixture was allowed to settle on ice for 15 mins and subsequently centrifuged at 10,000 rpm for 10 mins at 4 °C. The supernatant was carefully transferred to a new 5 mL Eppendorf (EP) tube and treated with running nitrogen to remove the methanol. The resulting liquid was freeze-dried at −80°C until further analysis. The freeze-dried powder was dissolved in 550 μL of PBS/D2O buffer (pH 7.4, 150 mM), which contained 0.05% TMSP-2,2,3,3-D4 (D, 98%) SODIUM-3-TRIMETHYLSILYLPROPIONATE (TSP, Cambridge Isotope Laboratories (CIL), Inc. #DLM-48, CAS #24493-21-8)). After thorough mixing, the solution was centrifuged at 10,000 rpm for 10 min at 4 °C. Finally, 500 μL of the supernatant was transferred into a 5 mm NMR tube (NORELL, #S55 SECURE SERIES) for analysis. |
Sampleprep Protocol Filename: | Tissue_preparation.pdf |
Processing Storage Conditions: | 4℃ |
Extract Storage: | 4℃ |
Analysis:
Analysis ID: | AN004948 |
Analysis Type: | NMR |
Results File: | ST003015_AN004948_Results.txt |
Units: | gauss |
NMR:
NMR ID: | NM000273 |
Analysis ID: | AN004948 |
Instrument Name: | 600 MHz Bruker Avance III |
Instrument Type: | FT-NMR |
NMR Experiment Type: | 1D-1H |
Spectrometer Frequency: | 600 MHz |
NMR Solvent: | H2O+D2O |